老年头癌最佳治疗结果 - - 三级癌症中心经验
Imtiaz Ahmed1, Sapna Krishnamurthy1, Rohan Bhise2
1Department of Radiation Oncology, KLES Belgaum Cancer Hospital and KLES Dr. Prabhakar Kore Hospital and MRC, Belgaum, India.
Journal of cancer research and therapeutics
|October 16, 2024
概括
化疗强度调节辐射疗法 (IMRT) 在患有局部晚期头癌 (LA-HNC) 的老年患者中耐受良好. 这种标准治疗方法产生了良好的临床结果,表明年龄不应该阻止患者获得最佳护理.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 头部和部癌症研究研究
背景情况:
- 患有局部晚期头癌 (LA-HNC) 的老年患者经常被排除在临床试验和标准并发化疗辐射之外.
- 这些患者通常仅接受放射治疗 (RT),可能会失去最佳治疗效益.
- 强度调节辐射疗法 (IMRT) 和支持性护理的进步可能允许在这个人口群体中考虑化疗辐射.
研究的目的:
- 为了前性地评估老年患者 (>65岁) 的治疗顺应性和临床结果,LA-HNC接受化疗-IMRT.
- 评估IMRT同步化疗在这个未研究的患者群体中的耐受性和疗效.
- 为了确定影响LA-HNC老年患者最终化疗-IMRT治疗结果的预后因素.
主要方法:
- 一项针对69名65岁以上的LA-HNC患者进行的前性研究,这些患者于2015年4月至2019年12月期间接受了LA-HNC治疗.
- 所有患者都接受了70 Gy IMRT,每周服用西斯普拉丁 (40 mg/m2) 或卡博普拉丁 (AUC-2).
- 评估结果包括治疗遵从性,局部区域控制 (LRC),整体存活率 (OS) 和毒性.
主要成果:
- 81%的患者完成了至少5次化疗周期,所有患者完成了70 Gy IMRT.
- 在64%的患者中观察到完全反应,随访时间中位数为23.6个月.
- 估计2年的LRC为60%,2年的OS为53.5%. 年龄较小 (<70岁),使用西斯普拉丁和完全反应与更好的生存状况有关.
结论:
- 绝对化疗-IMRT是LA-HNC老年患者耐受良好的治疗方法,取得了良好的临床结果.
- 这项研究表明,仅仅是晚年就不应该是LA-HNC标准化疗辐射治疗的禁忌.
- 这些发现支持将老年患者纳入LA-HNC的标准治疗方案.
更多相关视频
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Tertiary Healthcare System
1.7K
Specialized care provided over an extended period is called tertiary care. Usually, a primary or secondary care physician will refer a patient to tertiary care. A patient's maximum physical and mental function is restored in tertiary care, which is caused due to the impact of a chronic illness or condition. Tertiary care aims to achieve the highest level of functioning possible while managing chronic illness. For example, a patient who falls and fractures their hip will need secondary care...
1.7K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488


